Merck KGaA (ETR:MRK)
112.65
+1.00 (0.90%)
Jun 27, 2025, 5:35 PM CET
Merck KGaA Revenue
Merck KGaA had revenue of 5.28B EUR in the quarter ending March 31, 2025, with 3.13% growth. This brings the company's revenue in the last twelve months to 21.32B, up 2.38% year-over-year. In the year 2024, Merck KGaA had annual revenue of 21.16B with 0.78% growth.
Revenue (ttm)
21.32B
Revenue Growth
+2.38%
P/S Ratio
2.24
Revenue / Employee
340.49K
Employees
59,020
Market Cap
47.70B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 21.16B | 163.00M | 0.78% |
Dec 31, 2023 | 20.99B | -1.24B | -5.57% |
Dec 31, 2022 | 22.23B | 2.55B | 12.93% |
Dec 31, 2021 | 19.69B | 2.15B | 12.28% |
Dec 31, 2020 | 17.53B | 1.38B | 8.56% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius SE & Co. KGaA | 22.13B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Carl Zeiss Meditec AG | 2.17B |
Fielmann Group AG | 2.33B |
SCHOTT Pharma AG & Co. KGaA | 972.81M |
Merck KGaA News
- 9 days ago - Merck Foundation Chairman, CEO, and 14 First Ladies Inaugurate the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit in Dubai - Business Upturn
- 10 days ago - MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant - Financial Post
- 15 days ago - EQS-PVR: Merck KGaA: Correction of a release from 05/06/2025 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 18 days ago - China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor - Benzinga
- 18 days ago - China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor - Business Wire
- 18 days ago - China's Center for Drug Evaluation Accepts Merck's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor - Business Wire
- 23 days ago - EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 24 days ago - SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX - Wallstreet:Online